Research at the Institute of Biochemistry and Molecular Medicine (IBMM) focuses on the structure (Fotiadis), function (Abriel, Albrecht, Bütikofer, Charles, Fotiadis, Gertsch, Hediger, Li, Peinelt) and pharmacology (Abriel, Gertsch) of membrane proteins such as transporters, ion channels, and membrane receptors. A strong emphasis is put on the roles of these membrane proteins in human disease. We combine chemical synthesis (Lochner), chemical biology/analytics (Gertsch) with electrophysiology (Abriel, Li, Peinelt) and structural biology (Fotiadis). Both human ex vivo (Albrecht) and genetically-modified mouse models ( Abriel, Charles, Gertsch) serve to study these transporters in different diseases like cancer (Charles, Peinelt), cardiac disorders (Abriel, Li), preeclampsia (Albrecht) and neuropsychiatric disorders (Gertsch).
The IBMM directorate is composed of Dimitrios Fotiadis (Managing Director and Co-Director Finances), Jürg Gertsch (Deputy Managing Director and Co-Director Infrastructure and Research), Christine Peinelt (Co-Director Teaching) and Hugues Abriel (Co-Director Safety, Quality, and Equal Opportunities).
To apply excellence in membrane transporter research to the treatment of human diseases, the National Center of Competence in Research, NCCR TransCure, was established in 2010 and is currently led by Hugues Abriel and Jean-Louis Reymond. The IBMM is hosting most of the NCCR TransCure research groups from the University of Bern, which is the Leading House. For details see www.nccr-transcure.ch.
The specific focus areas of the individual research groups of the IBMM is shown in the section "Research"